NASDAQ$ZURA
Zura Bio Limited · Q3 2026 earnings
Q3 2026 earnings · · Before market open · Investor relations
Briefing
Zura Bio reported fiscal Q3 2026 results with a net loss of $24.2M as clinical-stage programs advanced.
Zura Bio reported a net loss of $24.2 million for the fiscal quarter ended March 31, 2026, compared with a $17.4 million loss a year ago, consistent with a clinical-stage biotech without product revenue. R&D and G&A spending increased with pipeline progression.
- Net loss $(24.2)M vs $(17.4)M prior-year quarter.
- Clinical-stage company; no product revenue in condensed statements.
- R&D investment for lead programs.
- Cash runway discussed in liquidity section.
- Fiscal Q3 period ended March 31, 2026.
Headline financials
Revenue & EPS history
Zura Bio · Revenue · Quarterly
$0
Forward guidance
Pre-commercial biotech; outlook tied to trial readouts and financing, not revenue/EPS guidance.
Tailwinds
- Pipeline advancement toward key data catalysts.
- Capital markets access for funding needs.
Headwinds
- Widening loss on higher development spend.
- Binary clinical and regulatory risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q3 2026
-1.2%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
36%
4 / 11 earnings
Positive
+22.8%
Q4 2023
Best reaction
-26.0%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -3.2% | -2.9% | -30.5% | |
| Q4 2025 | -9.5% | -17.3% | -13.2% | |
| Q2 2025 | +6.9% | +8.8% | +25.8% | |
| Q1 2025 | -7.6% | -14.2% | +0.0% | |
| Q4 2024 | +4.0% | +5.3% | -33.0% | |
| Q1 2024 | -0.6% | +9.6% | -14.9% | |
| Q4 2023 | +22.8% | +26.3% | +90.1% | |
| Q3 2023 | +2.8% | -1.2% | -4.2% | |
| Q2 2023 | -0.6% | -1.2% | +1.8% | |
| Q1 2023 | -26.0% | -28.5% | -3.0% | |
| Q4 2022 | -1.8% | -11.4% | -52.5% | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro